IL182898A0 - Contrast agents - Google Patents

Contrast agents

Info

Publication number
IL182898A0
IL182898A0 IL182898A IL18289807A IL182898A0 IL 182898 A0 IL182898 A0 IL 182898A0 IL 182898 A IL182898 A IL 182898A IL 18289807 A IL18289807 A IL 18289807A IL 182898 A0 IL182898 A0 IL 182898A0
Authority
IL
Israel
Prior art keywords
contrast agents
biomodifier
areas
human
general formula
Prior art date
Application number
IL182898A
Other languages
English (en)
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of IL182898A0 publication Critical patent/IL182898A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
IL182898A 2004-11-22 2007-05-01 Contrast agents IL182898A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Publications (1)

Publication Number Publication Date
IL182898A0 true IL182898A0 (en) 2007-08-19

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182898A IL182898A0 (en) 2004-11-22 2007-05-01 Contrast agents

Country Status (17)

Country Link
US (1) US8182790B2 (OSRAM)
EP (2) EP2243496A3 (OSRAM)
JP (2) JP5116480B2 (OSRAM)
KR (1) KR20070091609A (OSRAM)
CN (1) CN101107016B (OSRAM)
AT (1) ATE494913T1 (OSRAM)
AU (1) AU2005307195A1 (OSRAM)
BR (1) BRPI0518328A2 (OSRAM)
CA (1) CA2586621A1 (OSRAM)
DE (1) DE602005025911D1 (OSRAM)
ES (1) ES2358745T3 (OSRAM)
IL (1) IL182898A0 (OSRAM)
MX (1) MX2007006050A (OSRAM)
NO (1) NO20073039L (OSRAM)
RU (1) RU2007118385A (OSRAM)
WO (1) WO2006054904A2 (OSRAM)
ZA (1) ZA200705043B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
JP2010502585A (ja) * 2006-08-28 2010-01-28 ジーイー・ヘルスケア・リミテッド 68Ga標識ペプチド系放射性医薬品
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
US8466258B2 (en) 2007-12-13 2013-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
EP2732826B1 (en) 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
KR101430627B1 (ko) 2008-05-13 2014-08-14 유니버시티 오브 캔사스 금속 추출 펩타이드(map) 태그 및 관련된 방법
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2015085005A1 (en) * 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
AU641361B2 (en) 1988-05-02 1993-09-23 Zynaxis Technologies, Incorporated Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
NZ335799A (en) 1996-10-28 2000-11-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
ES2257771T3 (es) * 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
CA2278200A1 (en) * 1997-01-29 1998-07-30 Nycomed Imaging As Polymers
EP1037947B1 (en) 1997-07-28 2003-09-10 Amersham plc Cyanine dyes
US5942637A (en) * 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
PT1075277E (pt) * 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
NZ521735A (en) 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
CA2429956A1 (en) * 2000-11-27 2002-07-18 Alan P. Carpenter, Jr. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
JP4510444B2 (ja) * 2001-07-10 2010-07-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
DE60324471D1 (de) 2002-06-17 2008-12-11 Cartela R & D Ab Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
CN1968963A (zh) * 2004-06-16 2007-05-23 通用电气医疗集团股份有限公司 基于肽的化合物
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物

Also Published As

Publication number Publication date
MX2007006050A (es) 2007-11-14
NO20073039L (no) 2007-08-16
CN101107016A (zh) 2008-01-16
WO2006054904A2 (en) 2006-05-26
ZA200705043B (en) 2008-09-25
CA2586621A1 (en) 2006-05-26
US20090208412A1 (en) 2009-08-20
AU2005307195A1 (en) 2006-05-26
BRPI0518328A2 (pt) 2008-11-11
WO2006054904A3 (en) 2007-04-05
JP2012207027A (ja) 2012-10-25
KR20070091609A (ko) 2007-09-11
DE602005025911D1 (de) 2011-02-24
JP2008520658A (ja) 2008-06-19
ES2358745T3 (es) 2011-05-13
JP5116480B2 (ja) 2013-01-09
CN101107016B (zh) 2011-11-16
ATE494913T1 (de) 2011-01-15
EP1814598B1 (en) 2011-01-12
EP2243496A3 (en) 2012-12-26
RU2007118385A (ru) 2008-12-27
EP2243496A2 (en) 2010-10-27
US8182790B2 (en) 2012-05-22
EP1814598A2 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
IL182898A0 (en) Contrast agents
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
WO1998018497A3 (en) Contrast agents
DE60234057D1 (de) Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO1998018496A3 (en) Contrast agents
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
IL145830A (en) Glucagon-like peptide-1 compositions for use in treating myocardial tissue injury
AU2003243226A1 (en) Vitamin-mitomycin conjugates
EP1409544A4 (en) HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS
BG100192A (en) 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
ATE243230T1 (de) Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
EP2962699A3 (en) Improved method for preparing conjugates of proteins and chelating agents
NO20052925D0 (no) Vannloselige anioniske bakterieklorofyllderivater og deres anvendelse
WO2004110255A3 (en) Antineoplastic agents targeted via glut transporters
ATE425770T1 (de) Kontrastmittel
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
WO2010032248A3 (en) Multifunctional albumin conjugates
DE602004029016D1 (de) Stq-peptide
EP1250091A4 (en) HYDROPHILE CYANINE DYES
NZ595758A (en) Thorium-227 for use in radiotherapy of soft tissue disease